Canada
The next-generation Closed-System Drug-Transfer Device (CSTD) from BD that advances hazardous drug protection
The BD PhaSeal™ System pioneered the category of closed-system drug transfer devices (CSTDs) to help protect the pharmacists and clinicians who prepare and administer hazardous drugs. 20 years later, we turned to healthcare professionals like you for feedback and guidance to optimize its every component. The result is the BD PhaSeal Optima System—a next-generation, user-tested CSTD solution that advances hazardous drug safety.
Every component of the BD PhaSeal Optima System is designed with no inlets or air exchange for airtight hazardous drug transfers. Click on each hot spot below to see how we have also optimized ease of use, ergonomics and performance.
The BD PhaSeal Optima System replaces the push-turn-push connection mechanism of the BD PhaSeal System with a one-step straight-push mechanism, making it easier for pharmacists and clinicians to use.
Designed to help minimize the learning curve with:
Let our trained clinical specialists help you efficiently integrate the BD PhaSeal Optima System into the workflow of your facility.
We conducted head-to-head comparisons and asked both longstanding CSTD users and traditional technique users how we could improve our design. The feedback and validation we received guided us to optimize every component of the BD PhaSeal Optima System for user comfort.
Our trained clinical specialists can also help train your pharmacists and clinicians in best practices for preparation and administration using BD PhaSeal Optima.
In a performance comparison, the BD PhaSeal Optima System demonstrated the lowest residual fluid loss of all four CSTDs tested.2,3 Minimizing residual fluid loss with such a CSTD may translate into a reduction in drug waste that can help optimize preparation of HDs and increase cost savings for your facility. 4,5
Minimizing this waste could enable hospitals and healthcare professionals to provide sufficient doses of drugs while using fewer vials, which could lead to cost savings.2 It could also help to align patient and facility expenditures on drugs more closely with the actual amount of medicine used.2
Contact us to get started
We can share the 'Minimizing residual drug loss' and 'Assessment of microbial ingress' whitepapers with you, and help you calculate potential drug savings for your facility.
The BD PhaSeal Optima System may help improve healthcare worker safety by reducing the risk of surface contamination to hazardous drugs. The BD PhaSeal Optima System incorporates the double membranes and vapor capture mechanisms pioneered by the BD PhaSeal System, which has been demonstrated to reduce the risk of hazardous drug exposure.
The BD PhaSeal Optima System meets the NIOSH definition of a CSTD that mechanically prohibits the transfer of environmental contaminants into the system and the escape of drug vapor concentrations outside the system, thereby minimizing individual and environmental exposure to drug vapor, aerosols and spills.
Contact us to get started
Let our trained clinical specialists help you seamlessly upgrade your facility to the BD PhaSeal Optima System.
BD PhaSeal™ Optima System instructional video for preparation
BD PhaSeal™ Optima System instructional video for administration
Protect clinicians and patients from exposure to hazardous drugs with a closed system
Get results in less than 10 minutes with the first and only rapid hazardous drug* detection system
BD offers training resources to help improve your clinical practices as part of our goal of advancing the world of health.
BD supports the healthcare industry with market-leading products and services that aim to improve care while lowering costs. We host and take part in events that excel in advancing the world of health™.
* Within an ISO Class V environment following aseptic technique
** 2015
^ The ability to prevent microbial ingress for up to 168 hours should not be interpreted as modifying, extending or superseding a manufacturer's labeling recommendations for the storage and expiration dating of the drug vial. Refer to drug manufacturer's recommendations and USP compounding guidelines for shelf life and sterility information.
BD-17517 (05/21)